Cyclacel Pharmaceuticals Inc represents values of innovation, dedication, and patient-centricity in the pharmaceutical industry. With a strong corporate philosophy focused on developing breakthrough therapies, Cyclacel is committed to improving the lives of patients through advanced research and development. By harnessing cutting-edge science and technology, Cyclacel aims to provide novel treatment options for various diseases, addressing unmet medical needs. The company's dedication to scientific excellence and a patient-first approach guides its pursuit of transforming healthcare outcomes. Cyclacel Pharmaceuticals Inc strives to deliver high-quality, effective, and safe medications to enhance the well-being of patients worldwide.

Cyclacel Pharmaceuticals Inc is primarily present in the United States.

Cyclacel Pharmaceuticals Inc. has achieved significant milestones in its journey. The company successfully completed the Phase 3 SEAMLESS study for its lead product candidate, sapacitabine, in patients with acute myeloid leukemia (AML). This paved the way for potential regulatory approvals, bringing hope to AML patients worldwide. Cyclacel Pharmaceuticals Inc. also received Fast Track designation from the U.S. FDA for sapacitabine, recognizing its potential to address unmet medical needs. Furthermore, the company has made significant progress in developing other innovative oncology therapies, positioning itself as a key player in the biopharmaceutical industry. Cyclacel Pharmaceuticals Inc.'s achievements demonstrate its commitment towards advancing cancer treatment options for patients.

Cyclacel Pharmaceuticals Inc is a renowned biopharmaceutical company specializing in developing targeted medicines for the treatment of cancer and other serious diseases. Founded in 1996, Cyclacel has made significant contributions to the field of oncology research. The company is committed to developing innovative therapies that enhance patient outcomes and improve the overall quality of life. With a strong focus on personalized medicine, Cyclacel Pharmaceuticals Inc employs a proprietary platform technology to identify and develop novel, cell cycle-based drugs. The company's dedication to scientific excellence and transformative treatments has positioned it as a leader in the field of oncology.

Cyclacel Pharmaceuticals Inc faces competition from various companies in the market. Some of its main competitors include AstraZeneca, Pfizer, Eli Lilly, and Novartis. These pharmaceutical giants constantly strive to develop innovative drugs and therapies, just like Cyclacel Pharmaceuticals Inc. However, Cyclacel Pharmaceuticals Inc differentiates itself through its focus on developing targeted treatments for cancer and other serious diseases. With its unique research and development approach, along with a strong pipeline of potential drug candidates, Cyclacel Pharmaceuticals Inc remains dedicated to making a positive impact in the healthcare industry.

Cyclacel Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Cyclacel Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The company focuses on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases. Cyclacel develops small molecule drugs that target the cell cycle and promote apoptosis, a process of programmed cell death. The company utilizes its expertise in cell cycle biology to identify and develop potential drug candidates. Cyclacel aims to provide effective treatment solutions to enhance patient outcomes and improve quality of life.

Cyclacel Pharmaceuticals KGV ir -0,18.

Cyclacel Pharmaceuticals KUV ir 22,01.

AlleAktien kvalitātes vērtējums Cyclacel Pharmaceuticals ir 3/10.

gaidāmā Cyclacel Pharmaceuticals apgrozījums ir 60 690,00 USD.

gaidāmā Cyclacel Pharmaceuticals peļņa ir -7,34 milj. USD.

Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for various types of cancer. The business model of Cyclacel is based on the development of new and more effective cancer therapies, which are based on the research and development of new chemicals and drugs. The main business areas of Cyclacel include the research, development, marketing, and distribution of cancer treatment drugs. The company specializes in the development of cancer therapies that target enzymes in the body that promote the growth and proliferation of cancer cells. Cyclacel specializes in two types of cancer therapies: first, the development of small molecules that target cancer cells in the body and kill them or inhibit the growth of cancer cells. Secondly, the development of combination therapies that target multiple enzymes simultaneously and effectively inhibit the growth of cancer cells. An important part of Cyclacel's business is the research and development of new drugs. The company works with academic research institutes and other companies to identify new target structures and substances that can serve as a basis for the development of new cancer therapies. Cyclacel has several products in various stages of clinical development, including Sapacitabine, Seliciclib, and CYC065. Sapacitabine is a cell cycle-selective chemotherapy for the treatment of MDS and leukemia. Seliciclib is a CDK inhibitor being developed for the treatment of ovarian cancer and other types of cancer. CYC065 is a CDK inhibitor used for the treatment of advanced tumors. Cyclacel also has a partnership with Beijing Shihai Pharmaceutical Company to distribute Seliciclib in China. Through this partnership, Cyclacel hopes to strengthen its presence in the Asian market and facilitate the distribution of its products in this important market. In summary, the business model of Cyclacel Pharmaceuticals aims to advance the research and development of new cancer therapies that effectively inhibit the growth of cancer cells. By identifying new target structures and substances and developing combination therapies, the company aims to further expand its presence in the cancer therapy market and solidify its position as a leading player in this field.

Cyclacel Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Cyclacel Pharmaceuticals vai uzņēmums nedod dividendes.

Cyclacel Pharmaceuticals ISIN ir US23254L6039.

Cyclacel Pharmaceuticals WKN ir A2P26W.

Cyclacel Pharmaceuticals simbols ir CYCC.

Pēdējo 12 mēnešu laikā Cyclacel Pharmaceuticals maksāja dividendes 0,15 USD apmērā. Tas atbilst aptuveni 9,55 % dividendes ražībai. Nākamajos 12 mēnešos Cyclacel Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Cyclacel Pharmaceuticals pašreizējā dividendu rentabilitāte ir 9,55 %.

Cyclacel Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cyclacel Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Cyclacel Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Cyclacel Pharmaceuticals apmērā 0,15 USD, kas tika izmaksāta 1.08.2016., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 13.07.2016..

Pēdējās dividendes izmaksa notika 1.08.2016..

Gadā 2023, Cyclacel Pharmaceuticals izmaksāja 0 USD dividendes.

Cyclacel Pharmaceuticals dividendes tiek izmaksātas USD.